Sichuan Goldstone Asia Pharmaceutical Inc. (SZSE:300434) entered into an Equity Acquisition Intention Agreement to acquire Jiangxi JuRenTang Pharmaceutical Company Limited from Hu Liuhe, Liu Min, Hu Xiaoping, and Hu Xuping on July 15, 2020. In the intention agreement it was agreed that, if the buyer and the sellers and related parties fail to sign a formal equity transfer agreement within 45 days from the date of signing this agreement, and this agreement is terminated or cancelled, Hu Liuhe, Liu Min, Hu Xiaoping, and Hu Xuping shall, within 45 days of signing of this agreement, the aforementioned deposit and interest shall be refunded to Sichuan Goldstone Asia Pharmaceutical Inc in full within 5 working days from the date of termination or termination of this agreement. In order to further improve the relevant matters related to the equity acquisition, when the signing date was about to expire 45 days, after negotiation, the two parties signed the "Equity Acquisition Intention Agreement Supplementary Agreement", extending the relevant time period of the "Equity Acquisition Intention Agreement" from 45 days. On September 29, 2020, after the two parties reached an agreement through consultation, the two parties signed the "Equity Acquisition Intention Agreement (2)" to extend the above-mentioned period to 95 days, and the other terms remained unchanged and continued to be implemented. Sichuan Goldstone Asia Pharmaceutical Inc. (SZSE:300434) cancelled the acquisition of Jiangxi JuRenTang Pharmaceutical Company Limited from Hu Liuhe, Liu Min, Hu Xiaoping, and Hu Xuping on October 19, 2020. The transaction was cancelled due to differences on the final transaction conditions and because the parties could not reach final consensus on the acquisition within the time limit and could not sign a formal acquisition agreement. The paid deposit will be refunded to Sichuan Goldstone Asia Pharmaceutical Inc. in the manner agreed in the intent agreement. The termination of the "Equity Acquisition Intention Agreement" and the supplementary agreement will not adversely affect the Jiangxi JuRenTang Pharmaceutical Company Limited's operating performance and financial status.